Detalhe da pesquisa
1.
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.
Cell
; 175(4): 998-1013.e20, 2018 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30388456
2.
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.
Cell
; 176(1-2): 404, 2019 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30633907
3.
Pre-T cell receptor self-MHC sampling restricts thymocyte dedifferentiation.
Nature
; 613(7944): 565-574, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36410718
4.
STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models.
Proc Natl Acad Sci U S A
; 119(28): e2111003119, 2022 07 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35787058
5.
Acute pharmacological degradation of Helios destabilizes regulatory T cells.
Nat Chem Biol
; 17(6): 711-717, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34035522
6.
Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge.
J Immunol
; 190(1): 469-78, 2013 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23225891
7.
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer.
Proc Natl Acad Sci U S A
; 108(30): 12372-7, 2011 Jul 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-21746896
8.
Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer.
Clin Cancer Res
; 30(9): 1934-1944, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38372707
9.
Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma.
J Clin Oncol
; 42(9): 1021-1030, 2024 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38252908
10.
Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial.
JAMA Oncol
; 10(1): 32-41, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37971722
11.
Development of a Patient-Derived 3D Immuno-Oncology Platform to Potentiate Immunotherapy Responses in Ascites-Derived Circulating Tumor Cells.
Cancers (Basel)
; 15(16)2023 Aug 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37627156
12.
Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1.
Cell Rep Med
; 4(11): 101282, 2023 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37992688
13.
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer.
Sci Immunol
; 8(87): eadf4968, 2023 09 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37683037
14.
Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study.
Front Oncol
; 12: 889996, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35747830
15.
MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer.
Cancer Res
; 82(21): 4079-4092, 2022 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36066413
16.
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck.
Clin Cancer Res
; 28(3): 468-478, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34667025
17.
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer.
Cancer Cell
; 40(10): 1128-1144.e8, 2022 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36150391
18.
Activation of Tumor-Cell STING Primes NK-Cell Therapy.
Cancer Immunol Res
; 10(8): 947-961, 2022 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35678717
19.
Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study.
Front Oncol
; 11: 696512, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34552864
20.
Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade.
J Clin Invest
; 131(2)2021 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33151910